Search

Displaying results 4171 - 4180 of 4286 in total
  1. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...

  2. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug.

  3. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).

  4. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  5. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its impr...

  6. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  7. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  8. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

  9. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.

  10. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    As of August, 2020 the candidate is in Phase II clinical trials[A219758].